Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 2, March-April, p. 343–349

doi: 10.17219/acem/63745

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: A meta-analysis and review of the literature

Guozhen Cui1,B,C,D, Shaoyan Zhang2,B,C,D, Jia Zou1,B,C,E, Yang Chen1,A,E, Hao Chen2,A,E,F

1 Zhuhai Key Laboratory of Basic and Applied Research in Chinese Medicine, Department of Bioengineering, Zunyi Medical University, Zhuhai, China

2 Longhua Hospital, Shanghai University of Traditional Chinese Medicine, China


A number of investigators have evaluated the association between T744C, G52T and C34T polymorphisms in the P2Y12 receptor gene and clopidogrel resistance (CR), but the results of their research are controversial. To quantify the evidence addressing this issue, we performed a meta-analysis of all available studies to evaluate the above association between the 3 different P2Y12 genotypes and CR in patients suffering from cardiovascular diseases. This study included articles up to October 2015. We performed a systematic search of PubMed, Embase, Web of Science, Cochrane database, China National Knowledge Infrastructure (CNKI) and WanFang database. Articles meeting the inclusion criteria were included and accumulated by meta-analysis including 5769 participants from 15 individual studies. For G52T polymorphism, a significant relationship between the P2Y12 receptor gene and CR was found under the dominant genetic model (p < 0.05). There was a clear positive correlation between the C34T polymorphism and CR under the dominant, recessive, additive genetic models, respectively (p < 0.05). The evidence from the present metaanalysis indicates that P2Y12 receptor gene C34T and G52T polymorphism might be a risk factor for the poor response to the platelet in patients on clopidogrel therapy, whereas a lack of association was found for T744C polymorphism examined by various genetic models.

Key words

polymorphism, cardiovascular diseases, resistance, clopidogrel, P2Y12

References (29)

  1. Hansson GK, Klareskog L. Pulling down the plug on atherosclerosis: Cooling down the inflammasome. Nat Med. 2011;17(7):790–791.
  2. Behan MW, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J. 2004;80(941):155–164.
  3. Hurst NL, Nooney VB, Raman B, et al. Clopidogrel “resistance”: Pre- vs post-receptor determinants. Vascul Pharmacol. 2013;59(5–6):152–161.
  4. Siller-Matula J, Schror K, Wojta J, et al. Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance. Thromb Haemost. 2007;97(3):385–393.
  5. Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003;108(8): 989–995.
  6. Galic E, Vrbanic L, Kapitanovic S, et al. P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation. Collegium antropo-logicum. 2013;37(2):491–498.
  7. Staritz P, Kurz K, Stoll M, et al. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP recep-tor gene. Int J Cardiol. 2009;133(3):341–345.
  8. Zoheir N, Abd Elhamid S, Abulata N, et al. P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coro-nary artery disease after coronary stenting. Blood Coagul Fibrinolysis. 2013;24(5):525–531.
  9. Liu YM, Liu NF. Evaluating association of P2Y12 gene polymorphisms with clopidogrel response variability in Chinese patients undergoing PCI. Journal of Southeast University. 2011;30(3):449–453.
  10. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
  11. Zhang SY, Chan SW, Zhou X, et al. Meta-analysis of association between ALDH2 rs671 polymorphism and essential hypertension in Asian populations. Herz. 2015;40:203–208.
  12. Chen XM, Jin J, Huang M, et al. Association between CYP2C19, P2Y12 genetic polymorphisms and clopidogrel resistance in ischemic stroke patients. China Pharmaci. 2014;17(6):885–888.
  13. Cuisset T, Frere C, Quilici J, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res. 2007;120(6):893–899.
  14. Lev EI, Patel RT, Guthikonda S, et al. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res. 2007;119(3):355–360.
  15. Shi HT, Zhou BR, Wang R, et al. Analysis of clinical characteristics of P2Y12 and CYP2C19 mutation genes and their relationship with the incidence of dynamic clopidogrel resistance in patients after cerebral infarction. J Apoplexy and Nervous Diseases. 2014;31(10):9–13.
  16. Shi ST, Li YJ, Zhang MJ, et al. Related factors of clopidogrel resistance in Han patients with cerebral infarction. J Shanxi Med Univ. 2013;44(12):953–956.
  17. Sun Y, Han YL, Zhang XL, et al. Association of T744C polymorphism of the P2Y12 gene with clopidogrel resistance in North Chinese patients of coronary artery disease. China Medical Engineering. 2011;19(04):44–47.
  18. Wang JJ. Influences of P2Y12 (C34T, G52T, iT744C). Polymorphisms on clopidogrel resistance in patients with coronary heart disease. Fujian Medical University. 2009:1–51.
  19. Bonello L, Bonello-Palot N, Armero S, et al. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thromb Res. 2010;125(4):167–170.
  20. Li XJ, Chen XM. Association between clopidogrel resistance and polymorphism of platelet adenosine diphosphate receptor in patients with coronary atherosclerotic disease. Journal of Zhejiang University-Science B. 2014;43(3):333–338.
  21. Zhao M, Chen BX, Du FH. Association between P2Y12 gene C34T and G52T platelet receptor polymorphisms and clopidogrel efficacy. Lab Med Clin. 2015;12(5).
  22. Tang XF, Zhang JH, Wang J, et al. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl). 2013;126(6):1069–1075.
  23. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113(3):340–345.
  24. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–1717.
  25. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25(14):1197–1207.
  26. Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet. 2001;29(3):306–309.
  27. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: Clinical implications, manage-ment, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–1516.
  28. Chen BL, Li Q, Xie W, et al. P2Y12 gene polymorphism in Chinese healthy population and patients with coronary artery disease and the association with effect of clopidogrel. Chinese Journal of New Drugs. 2008;17(16):1435–1439.
  29. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug inter-action. Circulation. 2003;107(1):32–37.